Kygevvi for Patients With Thymidine Kinase 2 Deficiency by Madaline Spencer| +++++

CLINICAL PERSPECTIVES Kygevvi for Patients With Thymidine Kinase 2 Deficiency https://checkrare.com/kygevvi-for-patients-with-thymidine-kinase-2-deficiency/ Kim Moran, Head of U.S. Rare Diseases at UCB, discusses the approval of Kygevvi (doxecitine and doxribtimine) for patients with thymidine kinase 2 deficiency (TK2d). The Use of Nipocalimab in Adolescent Patients With Generalized Myasthenia Gravis https://checkrare.com/the-use-of-nipocalimab-in-adolescent-patients-with-generalized-myasthenia-gravis/ Jonathan Strober, MD, pediatric neurologist and neuromuscular specialist at the University of California at San Francisco, discusses the use of nipocalimab in adolescent patients with generalized myasthenia gravis (gMG). EPIC Clinical Trial Design: Evaluating Nipocalimab Versus Efgartigimod in Patients With Myasthenia Gravis https://checkrare.com/epic-clinical-trial-design-evaluating-nipocalimab-versus-efgartigimod-in-patients-with-myasthenia-gravis/ Nolan Campbell, PhD, U.S. Medical Director at Johnson & Johnson, discusses the EPIC clinical trial design that will evaluate the efficacy of nipocalimab versus efgartigimod in patients with... Efficacy of Nipocalimab in Generalized and Ocular gMG: Long-Term Outcomes and Phase 3 VIVACITY-MG3 Findings https://checkrare.com/efficacy-of-nipocalimab-in-generalized-and-ocular-gmg-long-term-outcomes-and-phase-3-vivacity-mg3-findings/ Sindhu Ramchandren, MD, Executive Medical Director of Neuroscience at Johnson & Johnson, discusses long-term efficacy of nipocalimab in patients with generalized myasthenia gravis (gMG). ... The Shift to Precision Medicine in Myasthenia Gravis https://checkrare.com/the-shift-to-precision-medicine-in-myasthenia-gravis/ Alexandra C. Bayer Wildberger, PhD, Post-Doctoral Associate at Yale School of Medicine, discusses the shift to precision medicine in myasthenia gravis (MG).